VPTDF - Ventripoint Diagnostics Issues Shares in Payment of Consulting Fees
(TheNewswire)
Toronto, Ontario – TheNewswire –January 18, 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "),(TSXV:VPT ) ( OTC:VPTDF) announces it will issue an aggregate of666 ,666 shares to a consultant for $60,000 inconsulting fees at a deemed price of $0.09 per share, which was theclosing share price on September 30, 2020 and December 31, 2020 whenthe fees were due and payable.
The above issuance of shares is subject to the approval of theTSXV Exchange.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
Email :gadams@ventripoint.com
Phone: 519-803-6937 ?????
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Copyright (c) 2021 TheNewswire - All rights reserved.